Willow Biosciences Inc
Atlas Energy Corp., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical products in the United States. The company has licensing and development partnership with Laurus Labs to develop and commercialize active pharmaceutical ingredients and other ingredients. The company was formerly known as Willow Biosciences … Read more
Willow Biosciences Inc (CANSF) - Net Assets
Latest net assets as of September 2025: $27.96 Million USD
Based on the latest financial reports, Willow Biosciences Inc (CANSF) has net assets worth $27.96 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($28.12 Million) and total liabilities ($164.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $27.96 Million |
| % of Total Assets | 99.42% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -150.17% |
| Growth Volatility | 665.51 |
Willow Biosciences Inc - Net Assets Trend (2008–2024)
This chart illustrates how Willow Biosciences Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Willow Biosciences Inc (2008–2024)
The table below shows the annual net assets of Willow Biosciences Inc from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-505.00K | -114.70% |
| 2023-12-31 | $3.44 Million | -79.02% |
| 2022-12-31 | $16.37 Million | -44.84% |
| 2021-12-31 | $29.68 Million | +5409.84% |
| 2020-12-31 | $-559.00K | -102.54% |
| 2019-12-31 | $22.01 Million | +2535.68% |
| 2018-12-31 | $835.03K | +675.86% |
| 2017-12-31 | $-145.01K | +62.17% |
| 2016-12-31 | $-383.33K | -138.08% |
| 2016-06-30 | $1.01 Million | -8.49% |
| 2015-12-31 | $1.10 Million | -0.56% |
| 2014-12-31 | $1.11 Million | -17.80% |
| 2013-12-31 | $1.35 Million | +56.78% |
| 2012-12-31 | $858.34K | -65.46% |
| 2011-12-31 | $2.49 Million | -32.05% |
| 2010-12-31 | $3.66 Million | -25.70% |
| 2009-12-31 | $4.92 Million | +64.70% |
| 2008-12-31 | $2.99 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Willow Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12787400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $127.37 Million | % |
| Total Equity | $-505.00K | 100.00% |
Willow Biosciences Inc Competitors by Market Cap
The table below lists competitors of Willow Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Amtel Holdings Bhd
KLSE:7031
|
$2.85 Million |
|
Ralco Corporation Bhd
KLSE:7498
|
$2.85 Million |
|
Trimitra Propertindo Tbk PT
JK:LAND
|
$2.85 Million |
|
PMC LABEL MATERIALS PUBLIC COMPANY LIMITED
BK:PMC
|
$2.85 Million |
|
UPAY Inc
OTCQB:UPYY
|
$2.85 Million |
|
Sanwil Holding SA
WAR:SNW
|
$2.85 Million |
|
4Front Ventures Corp
OTCQX:FFNTF
|
$2.85 Million |
|
Enablence Technologies Inc
PINK:ENAFF
|
$2.85 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Willow Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,436,000 to -505,000, a change of -3,941,000 (-114.7%).
- Net loss of 6,189,000 reduced equity.
- New share issuances of 1,910,000 increased equity.
- Other factors increased equity by 338,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.19 Million | -1225.54% |
| Share Issuances | $1.91 Million | +378.22% |
| Other Changes | $338.00K | +66.93% |
| Total Change | $- | -114.70% |
Book Value vs Market Value Analysis
This analysis compares Willow Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-06-30 | $0.00 | $0.01 | x |
| 2016-12-31 | $-1.33 | $0.01 | x |
| 2017-12-31 | $-0.15 | $0.01 | x |
| 2019-12-31 | $0.28 | $0.01 | x |
| 2020-12-31 | $-0.01 | $0.01 | x |
| 2021-12-31 | $0.24 | $0.01 | x |
| 2022-12-31 | $0.13 | $0.01 | x |
| 2023-12-31 | $0.14 | $0.01 | x |
| 2024-12-31 | $-0.02 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Willow Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -132.75%
- • Asset Turnover: 1.87x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-88.02%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 0.00% | 0.00% | 0.00x | 1.26x | $-298.85K |
| 2009 | 0.00% | 0.00% | 0.00x | 1.06x | $-492.20K |
| 2010 | 0.00% | 0.00% | 0.00x | 1.06x | $-365.68K |
| 2011 | 0.00% | 0.00% | 0.00x | 1.20x | $-248.50K |
| 2012 | 0.00% | 0.00% | 0.00x | 2.37x | $-85.83K |
| 2013 | -96.60% | 0.00% | 0.00x | 1.66x | $-1.43 Million |
| 2014 | -62.62% | 0.00% | 0.00x | 1.76x | $-803.31K |
| 2015 | -405.25% | 0.00% | 0.00x | 1.17x | $-4.57 Million |
| 2016 | -130.19% | 0.00% | 0.00x | 2.40x | $-1.41 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.29 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.84 Million |
| 2018 | -196.95% | -9723.67% | 0.02x | 1.16x | $-1.73 Million |
| 2019 | -202.49% | -972220.55% | 0.00x | 1.54x | $-46.77 Million |
| 2020 | 0.00% | -339460.00% | 0.00x | 0.00x | $-33.89 Million |
| 2021 | -20.69% | -4616.54% | 0.00x | 1.18x | $-9.11 Million |
| 2022 | -90.47% | -1804.38% | 0.05x | 1.11x | $-16.45 Million |
| 2023 | -379.19% | -1111.69% | 0.18x | 1.94x | $-13.37 Million |
| 2024 | 0.00% | -132.75% | 1.87x | 0.00x | $-6.14 Million |
Industry Comparison
This section compares Willow Biosciences Inc's net assets metrics with peer companies in the Oil & Gas Midstream industry.
Industry Context
- Industry: Oil & Gas Midstream
- Average net assets among peers: $1,366,985,791
- Average return on equity (ROE) among peers: 2492.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Willow Biosciences Inc (CANSF) | $27.96 Million | 0.00% | 0.01x | $2.85 Million |
| Antero Midstream Partners LP (AM) | $142.86 Million | 0.00% | 0.21x | $7.58 Billion |
| AltaGas Ltd (ATGFF) | $2.83 Billion | 7.11% | 1.57x | $8.06 Billion |
| ATGPF (ATGPF) | $7.86 Billion | 8.56% | 1.98x | $4.11 Billion |
| Avance Gas Holding Ltd (AVACF) | $603.79 Million | 27.09% | 0.91x | $7.70K |
| CBL International Limited Ordinary Shares (BANL) | $12.11 Million | 30.42% | 1.11x | $3.17 Million |
| BP Prudhoe Bay Royalty Trust (BPT) | $863.00K | 22418.66% | 0.16x | $2.99 Million |
| Brooge Holdings Ltd (BROG) | $78.49 Million | 16.31% | 4.83x | $32.39 Million |
| Brooge Energy Limited (BROGW) | $56.77 Million | -85.14% | 7.56x | $5.67K |
| Cool Company Ltd (CLCO) | $715.51 Million | 11.75% | 1.88x | $145.96 Million |